Tilman Todenhöfer

8PUBLICATIONS
55CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Biomedical imagingMedical biotechnology diagnostics (incl. biosensors)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 20, 2025
ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer.

Gillian Vandekerkhove, Andrew J Murtha, David C Müller

|Apr 17, 2025
On the Horizon: A Global Multidisciplinary Perspective on Delivering Emerging Therapies for Patients with BCG-Naïve High-Risk NMIBC.

Bernadett E Szabados, Félix Guerrero-Ramos, Enrique Grande

|Feb 11, 2021
Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB.

Tilman Todenhöfer, Moritz Maas, Miriam Ketz

|Jul 11, 2020
Role of Multiparametric Magnetic Resonance Imaging in Predicting Pathologic Outcomes in Prostate Cancer.

Niklas Harland, Arnulf Stenzl, Tilman Todenhöfer

|Dec 31, 2019
Intratumoral Heterogeneity Determines the Expression of mTOR-pathway Proteins in Prostate Cancer.

Giorgio Ivan Russo, Jörg Hennenlotter, Ulrich Vogel

|May 14, 2019
Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review.

Simon Walz, Moritz Maas, Arnulf Stenzl

Pageof 2

Frequent Collaborators

5 joint publications

Arnulf Stenzl

2 joint publications

Steffen Rausch

1 joint publications

Simone Bier

1 joint publications

Simon Walz